Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00659425 | CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | completed | Phase 1 | 57 | MedImmune LLCINDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01495351 | Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma | completed | Phase 1 | 19 | AHS Cancer Control AlbertaOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT01078142 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma(BERT) | completed | Phase 1 / Phase 2 | 39 | Georg Hess, MDOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT01689987 | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02655458 | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | completed | Phase 1 | 15 | Hearn Jay ChoOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01393964 | Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT01042704 | Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 29 | Robert Redner, MDOTHER | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00500058 | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 | completed | Phase 1 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Jul 26, 2017 | clinicaltrials |
| NCT00992758 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 0 | Jul 25, 2017 | clinicaltrials |
| NCT01460420 | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation(EMN-alloRIC) | completed | Phase 1 / Phase 2 | 49 | European Myeloma Network B.V.NETWORK | 4 | Jul 6, 2017 | clinicaltrials |
| NCT00001512 | Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00001572 | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01786096 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | completed | Phase 1 | 92 | Seagen Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | completed | Phase 1 | 96 | Aptevo TherapeuticsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | completed | Phase 1 | 39 | Seagen Inc.INDUSTRY | 2 | Jun 28, 2017 | clinicaltrials |
| NCT00536835 | Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma | completed | Phase 1 | 41 | GlaxoSmithKlineINDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02155582 | Copanlisib Pharmacodynamic Study | completed | Phase 1 | 63 | BayerINDUSTRY | 3 | Jun 16, 2017 | clinicaltrials |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00724568 | Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma(RVDD) | completed | Phase 1 / Phase 2 | 74 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00603447 | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 1 | 84 | AmgenINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT01980589 | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects(CHAMPION 2) | completed | Phase 1 | 22 | AmgenINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01582295 | XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | completed | Phase 1 | 4 | Massachusetts General HospitalOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03057418 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | completed | Phase 1 | 7 | Biointegrator LLCINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | Phase 1 | 48 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | Phase 1 | 26 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01226849 | Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma(SGH652) | completed | Phase 1 | 6 | Singapore General HospitalOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT00693602 | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma | completed | Phase 1 | 87 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT00923910 | Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 12, 2017 | clinicaltrials |
| NCT00446342 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | completed | Phase 1 | 21 | Sunesis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00005988 | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma(ATLL) | completed | Phase 1 / Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01900509 | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 16 | St. Jude Children's Research HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT00733824 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | Mar 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2017source: clinicaltrials